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Natural killer cells are the first lymphocyte population to reconsti-tute early after non-myeloablative and T cell-replete haploidenti-cal hematopoietic stem cell transplantation with post-transplant
infusion of cyclophosphamide. The study herein characterizes the tran-
sient and predominant expansion starting from the second week follow-
ing haploidentical hematopoietic stem cell transplantation of a donor-
derived unconventional subset of NKp46neg-low/CD56dim/CD16neg natural
killer cells expressing remarkably high levels of CD94/NKG2A. Both
transcription and phenotypic profiles indicated that unconventional
NKp46neg-low/CD56dim/CD16neg cells are a distinct natural killer cell subpop-
ulation with features of late stage differentiation, yet retaining prolifera-
tive capability and functional plasticity to generate conventional
NKp46pos/CD56bright/CD16neg-low cells in response to interleukin-15 plus
interleukin-18. While present at low frequency in healthy donors,
unconventional NKp46neg-low/CD56dim/CD16neg cells are greatly expanded
in the seven weeks following haploidentical hematopoietic stem cell
transplantation, and express high levels of the activating receptors
NKG2D and NKp30 as well as of the lytic granules Granzyme-B and
Perforin. Nonetheless, NKp46neg-low/CD56dim/CD16neg cells displayed a
markedly defective cytotoxicity that could be reversed by blocking the
inhibitory receptor CD94/NKG2A. These data open new and important
perspectives to better understand the ontogenesis/homeostasis of
human natural killer cells and to develop a novel immune-therapeutic
approach that targets the inhibitory NKG2A check-point, thus unleash-
ing natural killer cell alloreactivity early after haploidentical hematopoi-
etic stem cell transplantation.  
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ABSTRACT
Introduction
The development over recent years of new protocols of allogeneic bone marrow
transplant (BMT) arises from the need to rapidly identify a reliable source of
hematopoietic stem cells (HSCs) to cure life-threatening hematologic malignan-
cies. Indeed, the possibility of having a donor for nearly every patient requiring a
BMT pushed the optimization of different haploidentical
HSC transplants (hHSCT) that combined different condi-
tioned regimes and immune-modulation therapies.1 Both
myeloablative (MAC) and non-MAC (NMAC) T cell-
replete (TCRe) hHSCT followed by post-transplant
cyclophosphamide (Cy) gave remarkable positive clinical
outcomes.2-4 
Donor-derived immune-reconstitution (IR) is the most
important player ruling out either a positive or negative
clinical outcome of allogeneic HSCT.5 Natural Killer (NK)
cells are key for the prognosis of allogeneic BMT given
their ability to kill viral-infected or tumor-transformed
cells in the absence of a prior sensitization to specific
antigens.6-8 NK cell recognition of “self” relies on a large
family of inhibitory NK cell receptors (iNKRs) including
killer cell immunoglobulin-like receptors (KIRs) and C-
type lectins, such as CD94/NKG2A, which specifically
bind different alleles of major histocompatibility com-
plex of class I (MHC-I). A decreased expression or lack of
self-MHC-I on target cells unleash NK cell killing via the
engagement of several activating NK cell receptors
(aNKRs) (i.e., missing self hypothesis).9-11 In the context
of allogeneic and non-myeloablative BMT, the presence
of a “mismatch” between iNKRs and HLA alleles on
recipient cells induces a condition of alloreactivity that
makes it possible for donor-derived NK cells to: i) elimi-
nate recipient immune cells that survived the condition-
ing regimens (i.e., prevent graft reject), ii) kill recipient
antigen presenting cells (APCs) presenting host antigens
to donor T cells (i.e., avoid the onset of graft-versus-host
disease [GvHD]), and iii) clear residual malignant cells in
the recipient (i.e., induce graft-versus-leukemia [GvL]
effect). These NK cell-mediated effector-functions in
mismatched settings are being currently used to develop
adoptive NK cell transfer therapies to cure solid and
hematologic tumors.7,12 
Circulating NK cell subsets are normally defined on the
basis of CD56 and CD16 surface expression.
Conventional CD56bright/CD16neg-low (cCD56bright) NK cells
account for up to 10-15% of the total NK cell population,
and are able to secrete a high amount of pro-inflammatory
cytokines while displaying poor cytotoxicity. The conven-
tional CD56dim/CD16pos (cCD56dim) phenotype identifies
another highly cytotoxic subset that comprises up to 90%
of NK cells in the bloodstream.13 Other than the patholog-
ic NK subsets expanded in immunological disorders and in
response to pathogens,14 an additional population of
unconventional CD56dim/CD16neg (uCD56dim) NK cells has
been identified recently.15-17 Despite being rarely represent-
ed in healthy donors, uCD56dim is highly cytotoxic and
able to efficiently kill hematologic tumors 
in vitro.18 A subset of CD56low/CD16low NK cells resembling
the phenotype and functions of uCD56dim NK cells is
expanded in the bone marrow (BM) of healthy pediatric
donors and leukemic patients who have undergone a/b T
cell-depleted hHSCT.18,19
The study herein demonstrates that the NK cell IR in
TCRe -NMAC-PT/Cy hHSCT with reduced intensity
conditioning (RIC) are characterized by the early expan-
sion of donor-derived and anergic uCD56dim NK cells
showing a peculiar NKG2Apos/NKp46neg-low phenotype. We
also demonstrate herein that the blocking of the NKG2A
inhibitory pathway on this subset represents an
immunotherapeutic target to improve NK cell alloreactiv-
ity early after hHSCT. 
Methods
Study Design
30 patients were treated according to our published hHSCT
protocol approved by the institutional review boards (IRB) of
Humanitas Research Hospital.20 Patients and donors signed con-
sent forms in accordance with the Declaration of Helsinki.
Patients’ clinical features, enrolment criteria and timing of speci-
men collections are shown in the Online Supplementary Table
S1.21,22 Peripheral blood mononuclear cells (PBMCs) from healthy
volunteers or patients were isolated as previously described.22,23 
Flow cytometry and cell sorting
Cells were thawed in medium (Roswell Park Memorial Institute
[RPMI]-1640 supplemented with 10% fetal bovine serum (FBS),
1% penicillin-streptomycin and 1% L-glutamine) containing ben-
zonase nuclease (Sigma-Aldrich). Cells were stained for 15 min-
utes at room temperature (RT) with live/dead fixable dead cell
stain kit (Life Technologies) and 20 minutes at RT with fluores-
cent-conjugated monoclonal antibodies (mAbs). All mAbs are list-
ed in Online Supplementary Table S2. For Ki-67, Perforin and
Granzyme (GRZ)-B intracellular staining, cells were fixed and per-
meabilized using the Cytofix/Cytoperm kit (BD Biosciences)
according to the manufacturer's protocol. The gating strategy to
identify NK cells within total PBMCs is shown in Online
Supplementary Figure S1. Samples were acquired on a LSR Fortessa
and LSR II flow cytometers or fluorescence-activated cell sorting
(FACS)-sorted with FACS Aria III (BD Biosciences). NK cell
absolute counts were obtained by calculating the percentage with-
in the lymphocyte gate. Additional Methods are included in the
Online Supplementary Material 
Results
Preferential expansion of uCD56dim NK cells in the first
weeks after hHSCT
We identified CD14neg/CD3neg/CD20neg NK cell subsets in
peripheral blood (PB) and donor BM by polychromatic
flow cytometry on the basis of their CD56 and CD16 sur-
face expression within the lymphocyte gate.13 We did not
include CD56neg or NKG2Dneg lymphocytes in our gating
strategy, as these cells were contaminants lacking the NK
cell surface markers NKp46, NKG2A, Perforin and
Granzyme-B (Online Supplementary Figure S1). Our results
showed that the absolute numbers of circulating NK cells
in hHSCT recipients reach levels similar to those of their
healthy donors within four to five weeks after hHSCT
with a chimerism that is completely donor-derived after
28 days (Figure 1A,B). These findings confirmed that
donor-derived NK cells represent the first lymphoid com-
partment to immune-reconstitute in allogeneic HSCT
prior to T and B cells.6,7,21,22,24,25 
We then characterized the dynamic of circulating NK
cell subset IR early after hHSCT. Four distinct NK cell pop-
ulations were detectable in both healthy donors and
patients and their frequencies were remarkably different
within the several time points examined. First, we
observed that the frequency of cCD56bright NK cells was
significantly higher in the recipients compared to healthy
donors starting from the third week from the transplant,
and returned to similar physiologic levels 11 weeks after
hHSCT. Conversely, the percentage of the cCD56dim NK
cells was very low, if not undetectable, in the recipients
within the same period, and returned similar to that of
their related donors five months after the transplant. The
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low levels of cCD56dim NK cells early after hHSCT were
counterbalanced by a significant expansion the uCD56dim
NK cell subset which, instead, was present at low levels in
PB under homeostatic conditions. uCD56dim NK cells start-
ed to statistically increase in the recipients compared to
their related donors in the second week after the trans-
plant, outnumbered all other NK cell subsets in the second
and third week, and returned to normal level only eight
weeks after hHSCT. Different from Human Leukocyte
Antigen (HLA)-matched HSCT,26 CD56bright/CD16pos NK
cells did not increase in frequency at any time-point in
hHSCT recipients compared to their related donors
(Figure 1C,D). We and others have reported that the infec-
tion/re-activation with human cytomegalovirus (HCMV)
greatly influences the homeostasis and ontogenesis of NK
cell subset and induces the expansion of CD56neg/CD16pos
NK cells. This phenomenon is particularly relevant in the
immune-compromised recipients receiving allogeneic
HSCT.14 Although 23 of the 30 (77%) transplanted
patients recruited for this study experienced a HCMV
infection/reactivation starting from day 29 post hHSCT
up to day 64 following the transplant (Online
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Figure 1. Kinetic of NK cell subset immune reconsti-
tution after haploidentical HSCT. (A) Summary graph
showing the absolute counts (cells/μL) of circulating
natural killer (NK) cells (mean ± SEM) from
hematopoietic stem cell healthy donors (HDs) and
their related recipients at different time-points after
haploidentical HSCT (hHSCT). (B) Representative
example of flow cytometry dot plots showing the com-
plete chimerism of HD-derived HLA-A2neg NK cells
reconstituting an HLA-A2pos recipient (upper line) after
four and eight weeks from hHSCT (lower line). (C)
Representative example of flow cytometry dot plots
showing the kinetic of HD-derived NK cell subset dis-
tribution in the recipient after two, three, four and five
weeks from hHSCT. (D) Summary statistical graph
showing the frequency (median ± SEM) of convention-
al CD56bright/CD16neg-low (cCD56bright), CD56bright/CD16pos,
conventional CD56dim/CD16pos (cCD56dim) and uncon-
ventional CD56dim/CD16neg (uCD56dim) NK cell subsets
in the peripheral blood (PB) and bone marrow (BM) of
30 hematopoietic stem cell HDs compared to their
counterparts in the blood of the related recipients up
to six months after hHSCT. *P<0.05.
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Supplementary Table S1), neither the frequency (Online
Supplementary Figure S2A) nor the phenotype (data not
shown) of uCD56dim NK cells were affected over time by
this viral infection. 
Even though the existence and the functional relevance
of uCD56dim NK cells have been previously reported,15-17 a
recent study claimed that the CD56dim/CD16neg phenotype
is induced by cryopreservation.27 To further validate our
experimental results performed on cryopreserved cells, we
compared the distribution of NK cell subsets between
freshly isolated and thawed PBMCs from healthy donors
and transplanted patients. Our results showed that both
frequencies and phenotypes of the four NK cell subsets
from cryopreserved PBMCs are similar to those of freshly
purified ones (Online Supplementary Figure S2B-D).
uCD56dim lymphocytes are bona fide NK cells 
To confirm that CD14neg/CD3neg/CD20neg uCD56dim lym-
phocytes are indeed NK cells, polychromatic flow cytom-
etry data from 11 healthy donors and from five patients
purified three weeks after hHSCT were labelled with a
unique computational barcode, concatenated and ana-
lyzed by the t-distributed Stochastic Neighbor Embedding
(t-SNE) algorithm.28 We arbitrarily identified 13 different
clusters (from C1 to C13) of non-T and non-B lympho-
cytes on the basis of population boundaries distinguish-
able on the t-SNE density plots (Figure 2A). We then deter-
mined the frequency of antigen expression in each cluster
by manual gating (Online Supplementary Figure S3), and dis-
played the results using a heat map. Figure 2B shows that
all clusters except C13 harbor several NK cell surface
markers at different degrees of expression. cCD56bright,
cCD56dim and uCD56dim NK cell subsets overlap across the
distinct clusters defined in the t-SNE map and show a sim-
ilar distribution in healthy donors and hHSCT recipients
(Figure 2C,D). cCD56bright are composed of C7, C8, C9 and,
as expected, are NKp46pos and NKG2Apos while expressing
low levels of Granzyme-B and Perforin. cCD56dim NK cells
are present at higher frequencies in healthy donors com-
pared to hHCST recipients and belong to C3, C4, C5, and
C6 groups. These cells are characterized by constitutive
high expressions of Granzyme-B and Perforin. uCD56dim
cells are comprised of C10, C11, C12 and are NKp46neg-low,
NKG2Dpos, Granzyme-Bpos and Perforinpos (Figure 2E). This
high-dimensional approach of polychromatic flow cytom-
etry data analysis, although applied to a small number of
hHSCT patients, indicate that uCD56dim cells are bona fide
NK cells. 
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Figure 2. Clustering of uCD56dim NK cells. (A) t-distributed Stochastic Neighbor Embedding (t-SNE) plot of lymphocytes from 11 healthy donors (HDs) and five recip-
ients at three weeks after haploidentical HSCT (hHSCT). CD3pos T (green on the left plot) and CD20pos B (orange on the left plot) cells are grouped within the t-SNE
map. Within the CD3neg/CD20neg gate (gray within the left plot), 13 (from C1 to C13) different clusters of lymphocytes were defined based on the population bound-
aries (right plot). (B) Heatmap showing the degree of expression of CD56, CD16, CD8, NKp46, NKG2A, NKG2D, Granzyme-B (GRM-B) and Perforin on the 13 clusters
of non-T and non-B lymphocytes defined in the right t-SNE plot of panel A. (C-D) t-SNE plots showing, within the 13 CD3neg/CD20neg clusters of lymphocytes presented
in panel B, the clusters of cCD56bright (blue), cCD56dim (black) and uCD56dim (red) NK cell subsets from HDs and from hHSCT-patients three weeks after HSCT together
(C) or separately (D). (E) Graphs showing the frequencies (median ± SEM) of cCD56bright, cCD56dim and uCD56dim from HDs and patients at three weeks after hHSCT
(w3) out of the total cells in each of the 13 clusters of CD3neg/CD20neg lymphocytes. 
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uCD56dim NK cells are not NK cell precursors and
express low levels of NKp46 
Ontogenetically, human NK cell precursors have been
divided into three main differentiation stages on the basis
of their different expression of several surface markers,
including CD34, CD117 and CD127. These precursors give
rise first to cCD56bright (stage 4) and then to terminally differ-
entiated cCD56dim (stage 5) NK cell subsets that are charac-
terized by a CD34neg/CD117neg/CD127neg phenotype and
express aNKRs (i.e., NKG2D and natural cytotoxicity recep-
tors [NCRs]).29,30 Our data showed that uCD56dim NK cells
from both healthy donors and hHSCT patients are
NKG2Dpos and NKp30pos, but do not express CD34, CD117
and CD127, thus proving that they are NK cells in later
A. Roberto et al.
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Figure 3. Phenotype of NK cell subsets in healthy donors and haploidentical HSCT patients. (A) Representative example of flow cytometry dot plots from a healthy
donors (HDs) and a patient after three weeks from haploidentical HSCT (hHSCT) showing the surface expression of CD117, CD34, CD127 and NKG2D on cCD56bright
(blue), cCD56dim (black) and uCD56dim (red) NK cells. The phenotypes of these representative NK cell subsets are overlaid with those of their viable lymphocytes (gray
background) used as positive controls. (B) Summary statistical graph showing the expression of CD34, CD117 and CD127 on cCD56bright (blue), cCD56dim (black) and
uCD56dim (red) from three HSC HDs and their recipients at three and five weeks after hHSCT. (C) Summary statistical graph showing the expression of NKG2D,
Granzyme-B, Perforin, NKp30, NKp46 on cCD56bright (blue), cCD56dim (black) and uCD56dim (red) from HSC HDs and their recipients after three and four weeks from
hHSCT. *P<0.05
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stages of differentiation rather than NK cell precursors
(Figure 3A,B). In line with their previously reported high
cytotoxicity,18 we also observed that uCD56dim NK cells
express high levels of Perforin and Granzyme-B.
Interestingly, we also found that uCD56dim NK cells have
low levels of NKp46, thus making this NCR an additional
phenotypic marker capable of distinguishing the latter sub-
set from both cCD56bright and cCD56dim NK cells (Figure 3C). 
uCD56dim NK cells expanded early after hHSCT have a
unique transcriptional profile
To gain more insights into the biological and functional
relevance of uCD56dim NK cells, we assessed the gene
expression profiles of FACS-sorted circulating NK cell sub-
sets from three healthy donors (three replicates for each of
the three cCD56bright, cCD56dim and uCD56dim NK cell sub-
sets) and from their three hHSCT recipients (three repli-
cates for each of the two cCD56bright and uCD56dim NK cell
subsets) three weeks after the transplant. In order to
reduce data dimensionality in three main directions, we
first analyzed our results via the principal component
analysis (PCA) algorithm. PCA showed that the transcrip-
tional signatures of NK cell subsets from healthy controls
are different from those of hHSCT patients (Figure 4A).
Moreover, the gene set enrichment analysis (GSEA) per-
formed on healthy donors and hHSCT patients indicates
that the majority of the gene sets enriched in the recipients
are associated with cell cycle, DNA repair and ribonucleic
acid (RNA) transcription (false discovery rate [FDR]
<0.00001) (Online Supplementary Table S3). Hence, donor-
derived NK cells early after hHSCT are activated and
endowed with high proliferative potential.   
We then analyzed the gene expression of cCD56bright,
uCD56dim and cCD56dim NK cells from healthy donors, and
determined that 3072 transcripts are differentially
expressed between these three NK cell subsets. These dif-
ferent transcriptional profiles were then compared with
those of uCD56dim and cCD56bright NK cells from patients.
Indeed, these latter two NK cell subsets were the only
ones to have expanded and be detectable three weeks
Unconventional CD56dim/CD16neg NK cells in HSCT
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Figure 4. Transcriptional profiles of NK cell subsets from healthy donors and patients three weeks after haploidentical HSCT. (A) Principal component analysis (PCA)
showing the gene expression profiles of cCD56bright, cCD56dim and uCD56dim NK subsets from healthy donors (HDs) and of cCD56bright and uCD56dim from patients after
three weeks from haploidentical HSCT (hHSCT). (B) Hierarchical clustering of NK cell subsets from healthy donors and patients three weeks after hHSCT. Sample
grouping, obtained from the expression levels of 3072 genes that are differentially expressed between cCD56bright, uCD56dim and cCD56dim NK cells from HDs. Yellow
and violet colors indicate decreased and increased expression, respectively. (C) Log2 expression fold-change (FC) in uCD56
dim from hHSCT patients versus cCD56bright
cells (x-axis), and versus cCD56dim cells (y-axis) from HDs. C1 and C2 boxes indicate the genes similarly expressed with cCD56dim from HDs but downregulated (C1)
and upregulated (C2) in uCD56dim from hHSCT versus cCD56bright from HDs. C3 box indicates the genes downregulated in uCD56dim from hHSCT versus cCD56dim from
HDs and similarly expressed with cCD56bright from HDs. Downmodulated genes highlighted in green and upmodulated genes highlighted in red are associated with
NK cell maturation, genes highlighted in violet are associated with NK cell activation or cytotoxicity.  
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after the transplant (Figure 1C,D). Supervised hierarchical
clustering revealed that in healthy donors uCD56dim NK
cells have a gene expression similar to that of cCD56dim
cells and different from that of cCD56bright NK cells. These
results were somewhat expected considering that both
uCD56dim and cCD56dim NK cells share a high degree of
cytotoxicity in physiological conditions.2 Although show-
ing distinct gene expression profiles, cCD56bright and
uCD56dim NK cells from hHSCT recipients group together
and are more similar to cCD56dim than cCD56bright NK cell
subsets from healthy donors (Figure 4B).
We then compared the fold change (FC) of the 3072 dif-
ferentially expressed genes between uCD56dim NK cells
from hHSCT patients and cCD56bright (FCx) or cCD56dim
(FCy) NK cells from healthy donors (Figure 4C). Among
those transcripts of uCD56dim NK cells from hHSCT
patients similarly expressed in cCD56dim NK cells from
healthy donors (FCy (log2) < |1|) but differently modulated
in cCD56bright NK cells from healthy donors (FCx (log2) >
|1|), we found a downregulation of CCR7, interleukin (IL)-
7R and TCF7 (Figure 4C1) as well as an upmodulation of
CCL3, CCL4, PRDM1 and IFN-γ (Figure 4C2).
Furthermore, uCD56dim NK cells from hHSCT patients
show an increased gene expression of NKp30, Perforin
(PRF), Granzyme (GRZ-B), GRZ-A and GRZ-H compared
to cCD56bright NK cells from healthy donors (Figure 4C2).
Among those transcripts of uCD56dim NK cells from
hHSCT patients similarly expressed in cCD56bright NK cells
from healthy donors (FCx (log2) < |1|) but differently mod-
ulated in comparison with cCD56dim NK cells from healthy
donors (FCy (log2) > |1|) we found a downregulation of the
maturation marker KLRG1 (Figure 4C3), of CD160 and
GRZ-M (Figure 4C3).
These transcriptional profiles parallel our flow cytome-
try data and confirmed our working hypothesis postulat-
ing that uCD56dim NK cells present at high frequencies
early after hHSCT are not NK cell precursors, but rather
represent lymphocytes in a later stage of differentiation
whose gene expression profile is intermediate between
cCD56bright and cCD56dim NK cells. 
Highly proliferating NKp46neg-low/uCD56dim cells can 
generate NKp46pos/cCD56bright NK cells 
Donor-derived uCD56dim and cCD56bright NK cell subsets
expressed high levels of Ki-67 (i.e., proliferating) at three
and four weeks after hHSCT, while their counterparts in
healthy donors were all Ki-67neg (i.e., quiescent)  (Figure
5A). These high rates of NK cell proliferation in hHSCT
are associated with the so-called “cytokine storm” which
occurs early after allogeneic transplant and induces
immune cell activation and differentiation to rapidly recu-
perate the recipients from the previously induced and life-
threatening condition of immunodeficiency.25,31 The prefer-
ential expansion of Ki67pos/uCD56dim NK cells starting from
the second week after hHSCT prompted us to hypothe-
size that they could generate either cCD56bright or cCD56dim
A. Roberto et al.
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Figure 5. FACS-sorted uCD56dim NK cells generate cCD56br NK cells under IL-15 and IL-18 stimulation. (A) Summary statistical graph showing the expression of Ki67
on cCD56bright (blue), cCD56dim (black) and uCD56dim (red) from HSC healthy donors (HDs) and their recipients after three and four weeks from hHSCT. (B)
Representative example from a HD of flow cytometry dot plots showing the purity of fluorescence-activated cell sorting (FACS)-sorted cCD56bright (blue), cCD56dim
(black) and uCD56dim (red) (left column) natural killer (NK) cell subsets. Highly pure and FACS-sorted NK cell subsets are overlaid with the phenotype of purified
CD3neg/CD20neg NK cells expressing CD56 and CD16 (gray). (C) Summary statistical graphs showing the proliferation index of FACS-sorted cCD56bright (blue) and
uCD56dim (red) NK cell subsets from six HDs at four, eight and 14 days of culture with interleukin (IL)-15+ IL-18. (D) Summary statistical graph showing the kinetic of
CFSE-diluting (CFSEdil) cCD56bright (blue), cCD56dim (black) and uCD56dim (red) NK cell subsets generated from FACS-sorted cCD56bright (upper panel) and uCD56dim (lower
panel) from seven HDs. No data are available for the cCD56dim NK cells, as they were not proliferating in response to IL-15 and IL-18. Data are expressed as means
± S.D.  *P<0.05; **P<0.01; ***P<0.001.  
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NK cells, whose frequencies in the recipient PB increase
over the following weeks (Figure 1C,D). To validate this
working hypothesis, we FACS-sorted uCD56dim,
cCD56bright and cCD56dim NK cells from healthy donors
(Figure 5B), cultured them with IL-15 plus IL-18 and ana-
lyzed the phenotype of proliferating cells diluting car-
boxyfluorescein succinimidyl ester (CFSE) at several time
points. IL-15 was chosen on the basis of its enhanced abil-
ity to prime NK cell proliferation and because it is
increased significantly in the blood of the recipient receiv-
ing allogeneic (including haploidentical) HSCT.25,31,32
Similarly, IL-18 is known to have a deep impact on NK cell
activation and effector-functions.33,34 In this regard, our
transcriptional data showed that IL-18 receptor-1 (IL-18-
R1) is significantly upregulated in uCD56dim NK cells from
hHSCT patients compared to cCD56dim NK cells from
healthy donors (FCy (log2) > |1|) (Online Supplementary
Table S4). In line with our transcriptional data (Figure 4),
we first observed that both uCD56dim and cCD56bright NK
cells highly proliferate in response to IL-15 and IL-18,
while terminally differentiated cCD56dim NK cells do not.
The proliferation index of cCD56bright NK cells is signifi-
cantly higher after 14 days of culture compared to those of
uCD56dim NK cells (Figure 5C and data not shown for
cCD56dim NK cells). Given the differential expression of
NKp46 on uCD56dim and cCD56bright NK cells (Figure 3C),
we analyzed the surface levels of this NCR to track the
fate of these two proliferating subsets. Although cycling at
a higher rate, only a minor and not statistically significant
fraction of FACS-sorted NKp46pos/cCD56bright NK cells gen-
erated NKp46neg-low/uCD56dim NK cells over time. Indeed,
the phenotype of proliferating cCD56bright NK cells was
similar (range 75-95%) to that of their resting and parental
counterparts at day 0. On the other hand, almost all pro-
liferating NKp46neg-low/uCD56dim NK cells gave rise to
NKp46pos/cCD56bright NK cells after 14 days of culture, and
only a minor fraction retained the NKp46neg-low/uCD56dim
phenotype. Finally, we observed that neither FACS-sorted
NKp46pos/cCD56bright NK cells nor FACS-sorted NKp46neg-
low/uCD56dim NK cells were able to generate cCD56dim NK
cells (Figure 5D and Figure 6).
uCD56dim cells expanded early after hHSCT are 
anergic due to high expression of NKG2A
Our phenotypic analyses showed that donor-derived
uCD56dim NK cells expanded early after hHSCT patients
are fully armed to efficiently kill tumor cell targets, as
already demonstrated in healthy donors.18 Surprisingly,
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Figure 6. Proliferating NKp46neg-low/uCD56dim NK cells differentiate in NKp46pos/cCD56bright NK cells. A) Representative example from a HD of flow cytometry dot plots
showing the expression of CD56 on fluorescence-activated cell sorting (FACS)-sorted and CFSE-diluting (CFSEdil) cCD56bright (blue) and uCD56dim (red) from a HD after
eight days in culture with interleukin (IL)-15 + IL-18. (B) Representative example from the same HD shown in panel A of flow cytometry histograms showing the level
of NKp46 expression, expressed as mean fluorescence intensity (MFI), after eight days in culture with IL-15 + IL+18  (MFI) on cCD56bright (blue line) and uCD56dim (red
line) natural killer (NK) cells derived either from FACS-sorted cCD56bright NK cells (blue) or from FACS-sorted uCD56dim NK cells (red). Overlaid gray histograms represent
the level of NKp46 expression on the relative freshly purified and FACS-sorted parental NK cells. (C) Summary statistical graph showing the kinetic of
NKp46pos/cCD56bright (blue) and of NKp46neg-low/uCD56dim (red) NK cell subsets generated from FACS-sorted cCD56bright (upper graph) and uCD56dim (lower graph) from
seven healthy donors. No data are available in panels B and C for cCD56dim NK cells, as they were not proliferating in response to IL-15 and IL-18. Data are expressed
as means ± S.D. *P<0.05; ***P<0.001. 
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we found the degree of CD107a degranulation against
K562 cell line of uCD56dim cells purified from hHSCT
recipients after six weeks from transplant is significantly
lower compared to that of their counterparts from healthy
donors (Figure 7A,B).
Considering that the cytolytic activity of NK cells is
licensed by the dominant regulation of iNKRs over
aNKRs,10,11 we screened the expression of a large panel of
inhibitory receptors, over time, that could likely explain
the anergy of donor-derived uCD56dim NK cells from
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Figure 7. Cytotoxicity of NKp46neg-low/uCD56dim from hHSCT patients expressing transient high levels of NK2A early after hHSCT. A) Representative example from a
healthy donor (HD) (lower line) of flow cytometry dot plots showing the expression of CD107a (i.e., cytotoxic natural killer [NK] cells) on cCD56bright (left), cCD56dim (mid-
dle) and uCD56dim (right) (left column) either in the absence (upper line) or in the presence (lower line) of K562. (B) Summary statistical graph showing the percentage
of CD107apos (median ± SEM) on cCD56bright (blue), cCD56dim (black) and uCD56dim (red) from five HDs and four patients after six weeks from haploidentical HSCT
(hHSCT). The background of CD107apos NK cells present in the spontaneous degranulation has been subtracted for the analyses performed in the presence of K562
cell line. (C) Summary statistical graph showing the expression of NKG2A on cCD56bright (blue), cCD56dim (black) and uCD56dim (red) from HSC HDs and their recipients
at different time points up to six months after hHSCT (medians ± SEM). (D) Summary statistical graph showing the percentage of CD107apos (median ± SEM) on
cCD56bright and uCD56dim NK cells from eight HDs and five patients after six weeks from hHSCT alone (-) or incubated (+) with 721.221G cell line, and either in the
absence (-) or in the presence (+) of the masking anti-CD94/NKG2A mAb (Y9). *P<0.05; **P<0.01. ns: not significant. 
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hHSCT recipients. We found that the NK cell expression
of CD94/NKG2A is remarkably increased after hHSCT. In
particular, while only a fraction (median of 47,2 %±2,5 %)
of uCD56dim NK cells from healthy donors is NKG2Apos,
almost all uCD56dim NK cells expanded after hHSCT
express this iNKR.  The significant higher frequency of
NKG2Apos/uCD56dim NK cells in the PB of recipients com-
pared to their related healthy donors is detectable
between the fourth and eleventh week following hHSCT
(Figure 7C). 
To understand if this high and transient expression of
CD94/NKG2A on donor-derived uCD56dim NK cells recon-
stituting the recipients could explain their defective cyto-
toxicity, we performed masking experiments by blocking
this iNKR in the presence of a tumor cell line expressing its
putative ligand HLA-E (i.e., 721-221G cell line).35,36 Both
cCD56bright and uCD56dim NK cells from healthy donors are
able to efficiently degranulate, and the masking with an
anti-CD94/NKG2A mAb increased the expression of
CD107a only in cCD56bright, in line with their high consti-
tutive expression of NKG2A. In contrast, both cCD56bright
and uCD56dim NK cells purified from hHSCT after six
weeks from the transplant are not able to efficiently
degranulate against 721-221G, and only the blocking of
the CD94/NKG2A inhibitory checkpoint significantly
increases the expression of CD107a of these NK cell sub-
sets (Figure 7D). 
Discussion
The recent development of TCRe-NMAC-PT/Cy
hHSCT with RIC represented a revolution in the field of
BMT for the cure of hematologic malignancies.1,2,37 The
study herein characterizes the transient and early expan-
sion of a functionally exhausted subset of donor-derived
uCD56dim NK cells that is detectable at a high frequency
from the second week after the transplant. uCD56dim NK
cells are by far the largest NK cell population in the first
weeks after hHSCT and are also characterized by a signif-
icant higher expression of CD94/NKG2A compared to
their counterparts in healthy donors. The increased sur-
face levels of this iNKR early after hHSCT greatly impairs
the cytotoxicity of uCD56dim NK cells, thus affecting those
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Figure 8. NK cell immune-reconstitution after haploidentical HSCT. (A) Natural killer (NK) cell ontogenesis (left): after the infusion of unmanipulated graft in non
myeloablative haplo- hematopoietic stem cells transplant (hHSCT), the reconstitution of NK cells in recipients is completely donor-dependent and starts from CD34pos
hematopoietic stem cells. Indeed, mature NK cells infused with the graft do not survive the PT infusion of cyclophosphamide.25 The first NK cell subsets to be detect-
ed starting from the second week after hHSCT are the cCD56bright and uCD56dim NK cells, with the latter population being by far the largest one, expanded early in the
first weeks after the transplant. cCD56bright and uCD56dim cells are not NK cell precursors and are able to exert a bi-directional differentiation following stimulation with
IL-15, a pro-inflammatory cytokine present at high levels in the sera of lymphopenic recipients in the first weeks after allogeneic transplant.25,31 (B) Clinical impact
(lower right): due to the high constitute expression of the inhibitory receptor NKG2A, uCD56dim NK cells are exhausted in their cytolic potential, and this impairment
greatly affects: i) the clearance of residual malignant cells in the recipient that survived the conditioning regimens (i.e., decreased graft-versus-leukemia (GvL) effect),
ii) the killing of recipient antigen presenting cells (APCs) presenting host antigens to donor T cells (i.e., increase in the onset of graft-versus-host disease [GvHD]),
and iii) the elimination of  recipient immune T cells that survived the conditioning regimens (i.e., decrease in engraftment).7 (C) Therapeutic insights (upper right):
the blocking of the NKG2A inhibitory checkpoint unleashes donor-derived NK cell cytotoxicity and increases their alloreactive potential. Hence, the PT infusion of the
humanized anti-NKG2A monoclonal antibody (i.e., Monalizumab) represents a potential novel therapeutic approach to improve the clinical outcome of hHSCT.    
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alloreactive NK cell effector functions that are required for
a positive clinical outcome of allogeneic HSCTs (Figure 8). 
It has recently been reported the PT/Cy in hHSCT kills
all mature and high proliferating NK cells infused in the
recipient with the graft. Indeed, NK cells do not express
aldehyde dehydrogenase, thus implying that the imma-
ture CD62Lpos/NKG2Apos/KIRneg NK cells reconstituting in
the recipients derive from donor HSCs.25 Nonetheless, the
kinetic and the clinical impact of NK cell subset distribu-
tion in this transplant setting are unknown. Even though
the absolute numbers of donor-derived NK cells are
restored in the recipients few weeks after the transplant,
we show herein that the distribution of their subset takes
much longer to acquire a pattern similar to that observed
in healthy donors.13 In particular, hHSCT recipients either
lack, or have very low frequencies, of circulating cCD56dim
NK cells soon after the transplant. The lack of the main
cytolytic population that normally accounts for  up to
90% of all circulating NK cells is compensated by the
expansion, starting from the second week after 
hHSCT of uCD56dim NK cells, that appear before cCD56dim
NK cells and that are present at a higher frequency com-
pared to cCD56bright NK cells early after the transplant. 
These findings prompted us to first hypothesize that
uCD56dim NK cells might represent an additional stage of
NK cell differentiation preceding the appearance of
cCD56bright and cCD56dim cell subsets. By focusing our
analyses on the different transcriptional profiles of NK cell
subsets from healthy donors, we first highlighted the
peculiar signature of the uCD56dim NK cell subset. These
data made it possible to understand how recipients are
repopulated over time by specific subsets of donor-
derived NK cells that are affected by the peculiar lym-
phopenic environment early after hHSCT, and follow a
kinetic highly impacting the functional outcome of the
transplant.   Indeed, both our transcriptional profiles and
phenotypic analyses in healthy donors and hHSCT recip-
ients showed that uCD56dim lymphocytes are bona fide NK
cells and not NK cell precursors, are not an artifact of cry-
opreservation, and express surface markers of late differ-
entiation such as NKG2D and NKp30 as well as lytic gran-
ules indicative of a cytotoxic phenotype. Our results are in
line with previous studies showing that uCD56dim NK cells
in healthy donors, although present at a very low frequen-
cy, represent a distinct subset able to efficiently kill tumor
cell targets.15-17 It has  also been reported that the lack or
decreased expression of CD16 on activated and degranu-
lating cCD56dim NK cells is mediated by the metallopro-
teinase-17 (ADAM17), thus potentially explaining, at least
in part, the origin of uCD56dim NK cells.38,39 Considering
that mature and highly proliferating NK cells infused with
the graft do not survive to the PT/Cy,25 it is highly unlikely
that the action of ADAM17 on activated cCD56dim NK
cells could alone explain the high frequencies of uCD56dim
NK cells early after hHSCT. Indeed, the expansion of this
latter circulating NK cell subset has its peak in the first
weeks after hHSCT, when cCD56dim NK cells are either
undetectable or present at very low frequencies (Figure
1C,D). Moreover, uCD56dim NK cells are characterized by
a remarkably high degree of cellular proliferation in
response to cytokine activation, are able to generate
cCD56bright NK cells, and express a NKp46neg-low phenotype.
These functional and phenotypic features do not belong to
terminally differentiated cCD56dim NK cells and are neither
induced nor mediated by mechanisms associated with
ADAM17 cleavage properties. As a matter of fact, we did
not find any difference in the transcriptional levels of
ADAM17 between cCD56dim and uCD56dim NK cells puri-
fied early after hHSCT (data not shown). Taken together,
these data indicate that ADAM17 likely plays a minor
role, if any, in the expansion of uCD56dim NK cells early in
hHSCT.
In the context of the cytokine storm characterizing the
systemic lymphopenic environment early after allogeneic
HSCT (including hHSCT), IL-15 certainly plays a key role
as it is highly increased in patients’ sera in the first week
after the transplant.25,31 Indeed, the incubation in vitro with
IL-15 plus IL-18 of FACS-sorted NKp46neg-low/uCD56dim
purified from healthy donors induces their proliferation
and preferential differentiation into NKp46pos/cCD56bright
NK cells over time. Only a minor fraction of proliferating
uCD56dim NK cells retains its parental phenotype follow-
ing activation. Additionally we found that, although to a
lesser and not statistically significant extent, a small frac-
tion of highly proliferating FACS-sorted
NKp46pos/cCD56bright NK cells generate NKp46neg-
low/uCD56dim NK cells. While these results demonstrate
that NKp46 represents an additional surface marker that
distinguishes uCD56dim NK cells from both cCD56bright and
cCD56dim NK cells, they leave unanswered the question
regarding the origin of uCD56dim NK cells. Nonetheless,
they indicate the presence of a bi-directional differentia-
tion between this latter subset and cCD56bright NK cells in
an ex vivo human setting mimicking a lymphopenic envi-
ronment highly enriched with IL-15. We are certainly
aware that this methodological approach does not resem-
ble the complex cellular and molecular interactions occur-
ring in the human BM niche during lymphopoiesis.
Indeed, neither uCD56dim nor cCD56bright NK cells were able
to generate terminally-differentiated cCD56dim NK cells, a
process that requires the presence of additional signals
delivered by fibroblasts, mesenchymal and stromal cells.40-
42 However, herein we clearly show that both proliferating
uCD56dim and cCD56bright NK cells can generate either
themselves or their “neighbor” NK cell subset. In this con-
text, the high serum level of IL-15 soon after hHSCT25
could  also be manipulated to boost a more potent anti-
tumor response by cCD56bright NK cells, as recently demon-
strated in multiple myeloma.43 Further studies are needed
in order to disclose the mechanisms that finely tune the
bi-directional transition between uCD56dim and cCD56bright,
both under physiologic conditions and in the lym-
phopenic setting following allogeneic HSCTs. 
Herein, we also demonstrate that the transcriptional
profile of uCD56dim NK cells expanded early after hHSCT
is distinct from that of their counterparts in healthy
donors. This is not surprising in the context of an allogene-
ic transplant where different stimuli, such as lymphope-
nia, alloreactivity, a high serum level of cytokines, antigen
stimulation, opportunistic viral infections and acute
GvHD highly influences the quantity and the quality of
IR.1,24,25 Indeed, this peculiar systemic environment
induces the preferential expansion starting from the sec-
ond week after hHSCT of uCD56dim NK cells which,
although showing a cytotoxic phenotype, are highly
defective in the clearance of tumor cell targets. This cellu-
lar functional exhaustion is associated, at least in part,
with the transient expression of CD94/NKG2A on all
uCD56dim NK cells that account for the majority of  the NK
cell population within the first weeks following trans-
A. Roberto et al.
1400 haematologica | 2018; 103(8)
plant. Indeed, the blocking of CD94/NKG2A with a mask-
ing mAb significantly increased the CD107a degranula-
tion as a marker of lytic activity of NK cells purified early
after hHSCT. Although the mechanism(s) inducing the
expansion of anergic NKG2Apos/uCD56dim NK cells is
unknown, this acquired knowledge now makes it possible
to develop a therapeutic approach targeting a specific
immune check-point whose inhibition can efficiently
increase NK cell alloreactivity within a given time-frame
after hHSCT. In this regard, the efficacy of the in vivo
administration of an anti-CD94/NKG2A blocking mAb
(i.e., Monalizumab) in improving NK cell cytotoxicity
against solid tumors and leukemic cells has been already
reported both in mice and humans.44,45 (clinicaltrials.gov
Identifier: 02459301) (Figure 8).  
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